Oddo BHF Asset Management Sas Has $6.94 Million Stock Holdings in Twist Bioscience Corporation $TWST

Oddo BHF Asset Management Sas boosted its position in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 7.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 145,960 shares of the company’s stock after acquiring an additional 10,310 shares during the period. Oddo BHF Asset Management Sas’ holdings in Twist Bioscience were worth $6,936,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Strs Ohio bought a new stake in shares of Twist Bioscience in the 1st quarter worth approximately $33,000. PNC Financial Services Group Inc. increased its position in shares of Twist Bioscience by 89.7% during the first quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after purchasing an additional 453 shares during the period. Quarry LP acquired a new position in shares of Twist Bioscience in the third quarter valued at $28,000. Strategic Advocates LLC raised its stake in shares of Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after purchasing an additional 906 shares in the last quarter. Finally, Fifth Third Bancorp bought a new position in Twist Bioscience in the first quarter worth $54,000.

Twist Bioscience Stock Down 3.5%

Shares of NASDAQ:TWST opened at $85.47 on Thursday. The company’s fifty day moving average is $83.72 and its 200-day moving average is $61.36. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $105.47. The company has a market capitalization of $5.32 billion, a PE ratio of -64.26 and a beta of 2.11.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The firm had revenue of $110.72 million for the quarter, compared to analyst estimates of $107.64 million. During the same quarter last year, the business earned ($0.66) EPS. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. Equities research analysts predict that Twist Bioscience Corporation will post -2.02 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Jan Johannessen sold 12,000 shares of Twist Bioscience stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $56.12, for a total value of $673,440.00. Following the completion of the transaction, the director owned 17,754 shares in the company, valued at approximately $996,354.48. The trade was a 40.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Emily M. Leproust sold 18,880 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $95.00, for a total value of $1,793,600.00. Following the completion of the transaction, the chief executive officer directly owned 824,039 shares in the company, valued at $78,283,705. The trade was a 2.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 50,211 shares of company stock valued at $4,199,331. Corporate insiders own 3.08% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on TWST shares. Robert W. Baird boosted their price target on shares of Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Tuesday, May 5th. Leerink Partners set a $110.00 target price on shares of Twist Bioscience in a research report on Thursday, July 16th. TD Cowen upped their target price on shares of Twist Bioscience from $68.00 to $89.00 and gave the company a “buy” rating in a research note on Monday, June 15th. Guggenheim lifted their price objective on Twist Bioscience from $60.00 to $107.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, Canaccord Genuity Group upped their price objective on Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $90.30.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.